Gender dysphoria in adolescents: can adolescents or parents give valid consent to puberty blockers?
clinical ethics
informed consent
legal aspects
minors/parental consent
sexuality/gender
Journal
Journal of medical ethics
ISSN: 1473-4257
Titre abrégé: J Med Ethics
Pays: England
ID NLM: 7513619
Informations de publication
Date de publication:
10 Mar 2021
10 Mar 2021
Historique:
received:
14
10
2020
revised:
25
01
2021
accepted:
08
02
2021
entrez:
11
3
2021
pubmed:
12
3
2021
medline:
12
3
2021
Statut:
aheadofprint
Résumé
This article considers the claim that gender diverse minors and their families should not be able to consent to hormonal treatment for gender dysphoria. The claim refers particularly to hormonal treatment with so-called 'blockers', analogues that suspend temporarily pubertal development. We discuss particularly four reasons why consent may be deemed invalid in these cases: (1) the decision is too complex; (2) the decision-makers are too emotionally involved; (3) the decision-makers are on a 'conveyor belt'; (4) the possibility of detransitioning. We examine each of these reasons and we show that none of these stand up to scrutiny, and that some are based on a misunderstanding of the nature and purposes of this stage of treatment and of the circumstances in which it is usually prescribed. Moreover, accepting these claims at face value could have serious negative implications, not just for gender diverse youth, but for many other minors and families and in a much broader range of healthcare settings.
Identifiants
pubmed: 33692171
pii: medethics-2020-106999
doi: 10.1136/medethics-2020-106999
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.